These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

533 related items for PubMed ID: 16430719

  • 1. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
    Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Barani L, Ferrannini E, Serio M.
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
    [Abstract] [Full Text] [Related]

  • 2. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
    Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Serio M, Miccoli P.
    Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
    [Abstract] [Full Text] [Related]

  • 3. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process.
    Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Romagnani P, Grosso M, Ferrannini E, Serio M.
    Eur J Endocrinol; 2006 May; 154(5):651-8. PubMed ID: 16645011
    [Abstract] [Full Text] [Related]

  • 4. Increase of interferon-γ inducible CXCL9 and CXCL11 serum levels in patients with active Graves' disease and modulation by methimazole therapy.
    Antonelli A, Ferrari SM, Corrado A, Ferrannini E, Fallahi P.
    Thyroid; 2013 Nov; 23(11):1461-9. PubMed ID: 23721189
    [Abstract] [Full Text] [Related]

  • 5. Influence of methimazole and radioactive iodine treatment in the serum levels of the chemokine CXCL10 in hyperthyroid patients with Graves' disease.
    Leite AC, Pedro AB, Romaldini JH.
    Horm Metab Res; 2011 Mar; 43(3):194-9. PubMed ID: 21283953
    [Abstract] [Full Text] [Related]

  • 6. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter.
    Antonelli A, Rotondi M, Fallahi P, Grosso M, Boni G, Ferrari SM, Romagnani P, Serio M, Mariani G, Ferrannini E.
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1485-90. PubMed ID: 17244787
    [Abstract] [Full Text] [Related]

  • 7. Elevated serum IL-16 and RANTES levels in patients with autoimmune thyroid diseases and modulation by methimazole therapy.
    Gu X, Zheng L, Chen X, Ruan L, Zhang H, Ge S, Zhu H, Lin X, Shen F.
    Horm Metab Res; 2012 Jun; 44(6):482-7. PubMed ID: 22473756
    [Abstract] [Full Text] [Related]

  • 8. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.
    Amato G, Mazziotti G, Sorvillo F, Piscopo M, Lalli E, Biondi B, Iorio S, Molinari A, Giustina A, Carella C.
    Bone; 2004 Sep; 35(3):785-91. PubMed ID: 15336617
    [Abstract] [Full Text] [Related]

  • 9. Thyroid hormone modulates insulin-like growth factor-I(IGF-I) and IGF-binding protein-3, without mediation by growth hormone, in patients with autoimmune thyroid diseases.
    Inukai T, Takanashi K, Takebayashi K, Fujiwara Y, Tayama K, Takemura Y.
    Horm Metab Res; 1999 Oct; 31(10):576-9. PubMed ID: 10596968
    [Abstract] [Full Text] [Related]

  • 10. Increased serum neopterin levels in patients with Graves' disease.
    Wagner R, Hayatghebi S, Rosenkranz M, Reinwein D.
    Exp Clin Endocrinol; 1993 Oct; 101(4):249-54. PubMed ID: 8307114
    [Abstract] [Full Text] [Related]

  • 11. Thyrotropin binding inhibiting immunoglobulins (TBII) in Graves' disease, toxic nodular goitre and autoimmune thyroiditis.
    Wägar G, Mäkinen T, Lamberg BA, Gordin A, Apter L, Pekonen F.
    Ann Clin Res; 1982 Apr; 14(2):83-9. PubMed ID: 6184007
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.